Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03601117 · ClinicalTrials.gov registry record · NA
Accelerated Intermittent Theta Burst Stimulation for Depressive Symptoms
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT03601117: Completed NA study, sponsored by Stanford University.
NCT03601117 is a NA study that has completed, run by Stanford University. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03601117, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study evaluates an accelerated schedule of theta-burst stimulation for depressive symptoms in psychiatric inpatients. A small pilot study (n=22) will be carried out to demonstrate feasibility, using the FDA-approved stimulation site for depression treatment (L-DLPFC). Participants will be offered stimulation at the anterior cingulate cortex (ACC).
Primary Outcome
A 10-item clinician-administered scale, designed to be particularly sensitive to antidepressant treatment effects in patients with major depression. Severity gradations for the MADRS have been proposed: 9-17 = mild depression, 18-34 = moderate depression, and ≥ 35 = severe depression. Scores range from 0-60 (higher scores are more symptomatic). Response is defined as a 50% reduction or greater in MADRS score compared to baseline. Remission is defined as a MADRS score of \<10. Data are presente
Interventions
- DEVICE Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation
- DEVICE Anterior Cingulate Cortex Accelerated Theta Burst Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2020-06-01 |
| Phase | NA |
What the finished NCT03601117 record still lists
NCT03601117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation is the first listed.
NCT03601117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03601117 about?
NCT03601117 is a clinical study titled "Accelerated Intermittent Theta Burst Stimulation for Depressive Symptoms". This study evaluates an accelerated schedule of theta-burst stimulation for depressive symptoms in psychiatric inpatients. A small pilot study (n=22) will be carried out to demonstrate feasibility, using the FDA-approved stimulation site for depression treatment (L-DLPFC). Participants will be offe...
What is the current status of trial NCT03601117?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2018-07-01. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03601117?
The interventions under investigation include: Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation (DEVICE), Anterior Cingulate Cortex Accelerated Theta Burst Stimulation (DEVICE).
Who is sponsoring clinical trial NCT03601117?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03601117's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI